by BroadcastMed
News and views from the world of clinical oncology and hematology.
Language
🇺🇲
Publishing Since
6/6/2019
Email Addresses
1 available
Phone Numbers
0 available
July 12, 2023
<p><span data-sheets-value= "{"1":2,"2":"<p>This week, we’re again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We’ll hear about findings in mesothelioma, small cell lung cancer, and drug development. </p><p>To listen to more podcasts from ASCO, visit <a href=\"https://www.asco.org/about-asco/asco-digital/podcasts\">asco.org/podcasts</a>. <br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’re again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We’ll hear about findings in mesothelioma, small cell lung cancer, and drug development. </span></p>
July 12, 2023
<p><span data-sheets-value= "{"1":2,"2":"<p>This week, we’re hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.</p><p>To listen to more podcasts from ASCO, visit <a href=\"https://www.asco.org/about-asco/asco-digital/podcasts\">asco.org/podcasts</a>. <br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’re hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.</span></p>
July 12, 2023
<p><span data-sheets-value= "{"1":2,"2":"<p>This week, we’ll discuss the findings of a study that examined the prevalence of <i>KRAS</i> G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">Prevalence of </a><i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">KRAS </a></i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">G12C Somatic Mutations by Cancer Type, Race, and Sex</a></p><p><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic </a><i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">ALK</a></i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">-Positive ALCL</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-previously-treated-patients-with-her2-positive-gastric-cancers/\">FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma/\" target=\"_blank\">FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma</a></p><p>To listen to more podcasts from ASCO, visit <a href=\"https://www.asco.org/about-asco/asco-digital/podcasts\">asco.org/podcasts</a>. <br><br><br><br><br><br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll discuss the findings of a study that examined the prevalence of <i>KRAS</i> G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.</span></p> <p><span data-sheets-value= "{"1":2,"2":"<p>This week, we’ll discuss the findings of a study that examined the prevalence of <i>KRAS</i> G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">Prevalence of </a><i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">KRAS </a></i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">G12C Somatic Mutations by Cancer Type, Race, and Sex</a></p><p><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic </a><i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">ALK</a></i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">-Positive ALCL</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-previously-treated-patients-with-her2-positive-gastric-cancers/\">FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma/\" target=\"_blank\">FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma</a></p><p>To listen to more podcasts from ASCO, visit <a href=\"https://www.asco.org/about-asco/asco-digital/podcasts\">asco.org/podcasts</a>. <br><br><br><br><br><br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:</span></p> <p><a href= "https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/"> <span data-sheets-value= "{"1":2,"2":"<p>This week, we’ll discuss the findings of a study that examined the prevalence of <i>KRAS</i> G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">Prevalence of </a><i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">KRAS </a></i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">G12C Somatic Mutations by Cancer Type, Race, and Sex</a></p><p><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic </a><i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">ALK</a></i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">-Positive ALCL</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-previously-treated-patients-with-her2-positive-gastric-cancers/\">FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma/\" target=\"_blank\">FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma</a></p><p>To listen to more podcasts from ASCO, visit <a href=\"https://www.asco.org/about-asco/asco-digital/podcasts\">asco.org/podcasts</a>. <br><br><br><br><br><br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Prevalence of <em>KRAS</em> G12C Somatic Mutations by Cancer Type, Race, and Sex</span></a></p> <p><a href= "https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/"> <span data-sheets-value= "{"1":2,"2":"<p>This week, we’ll discuss the findings of a study that examined the prevalence of <i>KRAS</i> G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">Prevalence of </a><i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">KRAS </a></i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">G12C Somatic Mutations by Cancer Type, Race, and Sex</a></p><p><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic </a><i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">ALK</a></i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">-Positive ALCL</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-previously-treated-patients-with-her2-positive-gastric-cancers/\">FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma/\" target=\"_blank\">FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma</a></p><p>To listen to more podcasts from ASCO, visit <a href=\"https://www.asco.org/about-asco/asco-digital/podcasts\">asco.org/podcasts</a>. <br><br><br><br><br><br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic <em>ALK</em>-Positive ALCL</span></a></p> <p><span data-sheets-value= "{"1":2,"2":"<p>This week, we’ll discuss the findings of a study that examined the prevalence of <i>KRAS</i> G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">Prevalence of </a><i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">KRAS </a></i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">G12C Somatic Mutations by Cancer Type, Race, and Sex</a></p><p><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic </a><i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">ALK</a></i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">-Positive ALCL</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-previously-treated-patients-with-her2-positive-gastric-cancers/\">FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma/\" target=\"_blank\">FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma</a></p><p>To listen to more podcasts from ASCO, visit <a href=\"https://www.asco.org/about-asco/asco-digital/podcasts\">asco.org/podcasts</a>. <br><br><br><br><br><br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> <a href= "https://ascopost.com/news/january-2021/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-previously-treated-patients-with-her2-positive-gastric-cancers/"> FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers</a></span></p> <p><span data-sheets-value= "{"1":2,"2":"<p>This week, we’ll discuss the findings of a study that examined the prevalence of <i>KRAS</i> G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">Prevalence of </a><i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">KRAS </a></i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">G12C Somatic Mutations by Cancer Type, Race, and Sex</a></p><p><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic </a><i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">ALK</a></i><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-systemic-alk-positive-alcl/\">-Positive ALCL</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-previously-treated-patients-with-her2-positive-gastric-cancers/\">FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers</a></p><p><a href=\"https://ascopost.com/news/january-2021/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma/\" target=\"_blank\">FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma</a></p><p>To listen to more podcasts from ASCO, visit <a href=\"https://www.asco.org/about-asco/asco-digital/podcasts\">asco.org/podcasts</a>. <br><br><br><br><br><br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> <a href= "https://ascopost.com/news/january-2021/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma/"> FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma</a></span></p>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
